Charles River Laboratories (CRL) Tops Q3 EPS by 8c; Narrows Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Charles River Laboratories Announces Third-Quarter 2017 Results from Continuing Operations
November 9, 2017 7:00 AM ESTThird-Quarter Revenue of $464.2 Million
Third-Quarter GAAP EPS of $1.09 and Non-GAAP EPS of $1.30
Updates 2017 Guidance
WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of 2017. Revenue from continuing operations was $464.2 million, an increase of 9.0% from $425.7 million in the third quarter of 2016. Revenue growth was driven primarily by the Discovery and Safety Assessment and Manufacturing Support segments.
The acquisitions of Agilux Laboratories and Brains On-Line contributed 2.7% to consolidated third-quarter revenue growth, both on a reported... More
